HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Neoadjuvant Pertuzumab/Trastuzumab Increases pCR Rate, Is Cost Neutral in HER2+ Breast Cancer in Real-World Setting

December 15th 2022

Neoadjuvant chemotherapy with dual HER2-blockade of pertuzumab and trastuzumab is well tolerated and increases the rate of pathological complete response in patients with HER2-positive breast cancer compared with regimens that contain trastuzumab only, while being neutral on drug cost.

Dr. Pakkala on Integrating Local Therapy into HER2+ Breast Cancer Treatment

December 15th 2022

Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.

DZD1516 With CSF Penetration Has Antitumor Activity in Heavily Pretreated HER2+ Metastatic Breast Cancer

December 14th 2022

DZD1516, a reversible and selective HER2 TKI with full blood–brain barrier penetration led to tumor responses, including in patients with baseline central nervous system metastases, in a phase 1 study of patients with metastatic HER2-positive breast cancer.

Real-world Data Confirm Safety Profile for Tucatinib Plus Trastuzumab/Capecitabine in HER2+ Breast Cancer

December 8th 2022

The safety profile for the combination of tucatinib, trastuzumab, and capecitabine from the phase 3 HER2CLIMB trial was confirmed with real-world data for patients with HER2-positive metastatic breast cancer.

Dr. Hurvitz on Trastuzumab Deruxtecan in Unresectable/Metastatic HER2+ Breast Cancer

December 7th 2022

Sara A. Hurvitz, MD, discusses updated survival data with fam-trastuzumab deruxtecan-nxki in HER2-positive, unresectable/metastatic breast cancer.

Trastuzumab Deruxtecan Continues to Best T-DM1 Survival Rates With Longer Follow-Up in HER2+ Metastatic Breast Cancer

December 7th 2022

Patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan compared with trastuzumab emtansine.

Trastuzumab Deruxtecan Generates PFS, OS Benefit Vs Capecitabine-based Regimens in Pretreated HER2+ Breast Cancer

December 7th 2022

Trastuzumab deruxtecan demonstrated a 64% reduction in the risk of disease progression or death compared with physician's choice of treatment in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who previously received ado-trastuzumab emtansine.

Dr. Krop on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

December 7th 2022

Ian Krop, MD, PhD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

Dr. Conlin on the Implications of the HER2-Low Subset in Breast Cancer

November 30th 2022

Alison K. Conlin, MD, discusses the inception of the HER2-low breast cancer treatment landscape.

Japan Approves Trastuzumab Deruxtecan for Previously Treated HER2+ Metastatic Breast Cancer

November 28th 2022

Japan’s Ministry of Health, Labor, and Welfare has approved trastuzumab deruxtecan for the treatment of adult patients with HER2-positive unresectable or recurrent breast cancer after prior chemotherapy, which includes trastuzumab and a taxane.

Advances in Breast Cancer Treatment Reshape Treatment Paradigms in 2022

November 21st 2022

The increasing role of antibody-drug conjugates have led to questions of sequencing for patients with HER2-positive breast cancer, whereas new data for first-generation PD-L1 inhibitors, such as pembrolizumab have shaken up the treatment paradigm for others.

Dr. Hurvitz on the Evolution of Targeted Therapies in HER2+ Breast Cancer

November 17th 2022

Sara A. Hurvitz, MD, discusses the evolution of targeted therapies in HER2-positive breast cancer.

Dr. Conlin on the Benefits of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

November 17th 2022

Alison K. Conlin, MD, discusses the benefits of trastuzumab deruxtecan in HER2-low breast cancer.

Trastuzumab Deruxtecan Produces Activity in Metastatic Breast Cancer With Brain Mets, Irrespective of HER2 Status

November 1st 2022

Fam-trastuzumab deruxtecan-nxki induced meaningful antitumor activity in patients with HER2-positive, HER2-low, or HER2-negative metastatic breast cancer who presented with brain metastases at baseline.

Treatment Opportunities Expand for HER2+ Breast Cancer With Brain Metastases

October 31st 2022

Suchita Pakkala, MD, discussed how treatments like tucatinib and fam-trastuzumab deruxtecan-nxki have widened the armamentarium for patients with brain metastases; the importance of enrolling these patients in clinical trials; and what future treatment sequencing might look like for this population.

Trastuzumab Deruxtecan Could Challenge Frontline Trastuzumab/Pertuzumab Combo in HER2+ Breast Cancer

October 27th 2022

Sara A. Hurvitz, MD, discusses the evolving treatment paradigm in HER2-positive breast cancer, ongoing research in the space, and developments in the treatment of triple-negative breast cancer.

Experts Navigate the New World of HER2-Positive Metastatic Breast Cancer

October 19th 2022

Treatment decisions in the second-line setting for patients with HER2-positive metastatic breast cancer are not as cut-and-dried as deciding between which data have the best outcomes.

Neoadjuvant Pegylated Liposomal Doxorubicin Regimen Has Promising Efficacy in HER2+ Breast Cancer

October 7th 2022

The combination of pegylated liposomal doxorubicin, cyclophosphamide, trastuzumab, and pertuzumab elicited encouraging responses with acceptable safety when given as neoadjuvant treatment in patients with HER2-positive breast cancer.

Trastuzumab Deruxtecan Expands Metastatic Breast Cancer Treatment Landscape Across HER2-Expressing Subtypes

October 7th 2022

Jane Lowe Meisel, MD, discussed the emergence of HER2-low as a new category in breast cancer, outlining the significance of the phase 3 DESTINY-Breast04 trial and the unique qualities of trastuzumab deruxtecan in the HER2-positive and HER2-low populations.

DZD1516 Demonstrates Safety, Early Activity in Heavily Pretreated Metastatic HER2+ Breast Cancer

October 6th 2022

DZD1516 monotherapy elicited early clinical activity and was found to be well tolerated in patients with HER2-positive metastatic breast cancer with or without brain metastases.